Granules India posts revenue of Rs 117.9 cr for Q2FY11

• Revenue of Rs. 117.9 Cr. 
• Net profit of Rs. 4.5 Cr.
• Standalone turnover at Rs. 100.2 Cr.

Granules India Ltd., a vertically integrated formulation manufacturer, announced financial results for its fiscal year 2011, second quarter ended September 30, 2010. On a consolidated basis, Granules posted revenue of Rs. 117.9 Cr. and a net profit of Rs. 4.5 Cr.

Quarter ended September 30, 2010

• Net Sales: Rs. 117.9 Cr., as compared to the same period last year at Rs. 114.5 Cr. 
• Net Profit: Rs. 4.5 Cr., as compared to the same period last year at Rs. 7.7 Cr. 
• EPS: Basic EPS was Rs. 2.26 as compared to the same period last year at Rs. 3.86

On a standalone basis, the Company achieved sales of Rs. 100.2 Cr. and a net profit of Rs. 5.3 Cr.

“We are continuing to diversify revenue from a division and product standpoint. The Company commercialized several finished dosage contracts this year and the division contributed nearly 20% of our revenue. From a product perspective, we have increased sales from ibuprofen, metformin and guaifenesin derived products. We will continue to take the necessary steps to increase the revenue mix from our portfolio of products so we are not dependent on one product.” said C. Krishna Prasad, Managing Director of Granules.

About Granules India Ltd.
(BSE: 532482, NSE: GRANULES)
Granules India Ltd. is a vertically integrated formulation manufacturer. The Company is a large-scale manufacturer of Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs), which are distributed in over 50 countries. The Company’s operations and logistics expertise along with its scale allow Granules to provide customers high quality products across the pharmaceutical manufacturing value chain at a cost-effective price.

Caution Statement:
Certain statements made above may be “forward looking statements” within the meaning of applicable laws and regulations.